Academic Journal
Cost-effectiveness analysis of bridge-to-transplantation temporary mechanical circulatory support versus non-bridged heart transplantation.
| Τίτλος: | Cost-effectiveness analysis of bridge-to-transplantation temporary mechanical circulatory support versus non-bridged heart transplantation. |
|---|---|
| Συγγραφείς: | Yin L; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., An X; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., Yang B; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., Zhou Z; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., Li Y; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., Wang C; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China., Bhuyan SS; Edward J. Bloustein School of Planning & Public Policy Rutgers, The State University of New Jersey, New Brunswick, NJ, United States., Si Y; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia., Wang P; Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China., Hu J; Henan Medical Communication and Project Forward Center, Zhengzhou, Henan, China., Zhang W; The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China.; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Tarimo CS; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.; Department of Science and Laboratory Technology, Dar es salaam Institute of Technology, Dar es Salaam, Tanzania., Wei J; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Li Q; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Shen Z; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Lu Q; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Miao Y; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China., Li X; Department of Health Management, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China. |
| Πηγή: | Frontiers in public health [Front Public Health] 2026 Jan 08; Vol. 13, pp. 1687327. Date of Electronic Publication: 2026 Jan 08 (Print Publication: 2025). |
| Τύπος έκδοσης: | Journal Article; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Lausanne : Frontiers Editorial Office |
| Ιατρικοί όροι (MeSH): | Heart Transplantation*/economics , Heart Failure*/surgery , Heart-Assist Devices*/economics , Cost-Benefit Analysis*, Bridge Therapy/economics ; Cost-Effectiveness Analysis ; Humans ; Retrospective Studies ; Female ; Male ; Quality-Adjusted Life Years ; Middle Aged ; China ; Adult ; Markov Chains |
| Περίληψη: | Objectives: Among patients undergoing heart transplantation, BTT-tMCS therapy demonstrates superior clinical efficacy compared to nonbridged HTx; however, its cost-effectiveness among Chinese patients remain uncertain. To evaluate the cost-effectiveness of BTT-tMCS therapy compared with nonbridged HTx among transplant-eligible Chinese patients from the healthcare payer's perspective. Methods: The cost-effectiveness analysis for this economic evaluation was conducted at a qualified heart transplantation center in Central China. Participants included patients admitted since 2018 who underwent either BTT-tMCS or nonbridged HTx, identified retrospectively from local electronic medical records and supplemented by corresponding questionnaires. Propensity score matching (PSM) was employed to obtain a homogeneous group of HTx patients to generate model input parameters. A Markov model simulates lifetime disease progression and associated costs for HTx patients, with monetary values standardized to 2023. Sensitivity analyses were performed to test the internal validity of the model's conclusions. The model evaluated two competing treatment strategies: BTT-tMCS and standard care. Lifetime health care cost and quality-adjusted life-years (QALYs) of the simulated cohort. Results: PSM identified 40 matched subjects who met the predefined criteria, creating a homogeneous cohort for analysis. Compared to nonbridged HTx, BTT-tMCS yielded higher lifetime incremental costs (510,361 RMB) and effects (5.88 QALYs), resulting in an ICER of 28966.88 RMB/QALY. Sensitivity analyses demonstrated the robustness of these findings, with a 90% probability of cost-effectiveness achieved at a willingness-to-pay threshold exceeding 80422.20 RMB/QALY. Conclusion: In this economic evaluation study, BTT-tMCS therapy was more likely to be cost-effective compared with non-bridged HTx. (Copyright © 2026 Yin, An, Yang, Zhou, Li, Wang, Bhuyan, Si, Wang, Hu, Zhang, Tarimo, Wei, Li, Shen, Lu, Miao and Li.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | J Heart Lung Transplant. 2023 Aug;42(8):1120-1130. (PMID: 37032222) J Heart Lung Transplant. 2017 Jan;36(1):82-90. (PMID: 27773454) Circulation. 2013 Jan 29;127(4):452-62. (PMID: 23271796) Clin Transplant. 2016 May;30(5):598-605. (PMID: 26913688) ESC Heart Fail. 2018 Feb;5(1):75-86. (PMID: 28741873) Lancet. 2024 Sep 14;404(10457):1019-1028. (PMID: 39236726) JAMA. 2018 Apr 10;319(14):1444-1472. (PMID: 29634829) J Card Fail. 2010 Nov;16(11):855-8. (PMID: 21055648) Circulation. 2024 Oct 22;150(17):1377-1390. (PMID: 39355918) J Am Heart Assoc. 2021 Aug 3;10(15):e019655. (PMID: 34315285) JAMA. 2024 Sep 10;332(10):842. (PMID: 39133480) Circulation. 2023 May 16;147(20):1489-1491. (PMID: 37186686) J Am Coll Cardiol. 2024 Jul 9;84(2):192-194. (PMID: 38960513) J Heart Lung Transplant. 2016 Sep;35(9):1116-23. (PMID: 27289301) J Thorac Cardiovasc Surg. 2013 Feb;145(2):566-73; discussion 573-4. (PMID: 23246055) J Heart Lung Transplant. 2016 Jan;35(1):1-23. (PMID: 26776864) Curr Atheroscler Rep. 2020 Apr 23;22(3):11. (PMID: 32328843) Nat Rev Cardiol. 2012 Jan 10;9(4):195-208. (PMID: 22231716) JACC Heart Fail. 2018 May;6(5):424-432. (PMID: 29724365) Eur J Cardiothorac Surg. 2013 Aug;44(2):195-7. (PMID: 23644711) Int J Cardiol. 2025 Mar 15;423:132997. (PMID: 39870119) Clin Res Cardiol. 2015 Feb;104(2):95-111. (PMID: 25349064) Circulation. 2023 Jul 25;148(4):336-353. (PMID: 37232170) Circulation. 2019 Feb 19;139(8):1080-1093. (PMID: 30779645) Metabolism. 2017 Apr;69S:S30-S35. (PMID: 28153356) J Heart Lung Transplant. 2022 Nov;41(11):1601-1610. (PMID: 36088174) J Am Coll Cardiol. 2020 Mar 31;75(12):1471-1487. (PMID: 32216916) J Heart Lung Transplant. 2021 Feb;40(2):149-157. (PMID: 33277169) J Heart Lung Transplant. 2020 Jul;39(7):619-626. (PMID: 32505492) Circ Heart Fail. 2020 Aug;13(8):e006971. (PMID: 32757643) J Am Heart Assoc. 2021 Sep 7;10(17):e021870. (PMID: 34465164) J Heart Lung Transplant. 2018 Jan;37(1):61-70. (PMID: 28754423) Lancet. 2013 Nov 16;382(9905):1638-45. (PMID: 24011548) J Heart Lung Transplant. 2018 Sep;37(9):1060-1066. (PMID: 29907499) J Heart Lung Transplant. 2024 Oct;43(10):1529-1628.e54. (PMID: 39115488) J Card Fail. 2018 Dec;24(12):860-863. (PMID: 30539718) Med Clin (Barc). 2006 Mar 18;126(10):373-5. (PMID: 16750126) J Thorac Cardiovasc Surg. 2014 Sep;148(3):1099-104; discussion 1104-5. (PMID: 24993619) Circulation. 2020 Oct 20;142(16):1602-1604. (PMID: 33074762) Lancet Public Health. 2024 Jun;9(6):e386-e396. (PMID: 38552651) Eur J Cardiothorac Surg. 2012 Jan;41(1):200-6; discussion 206. (PMID: 21640601) J Heart Lung Transplant. 2022 Feb;41(2):174-186. (PMID: 34922821) J Card Fail. 2022 Jul;28(7):1149-1157. (PMID: 35470056) JACC Heart Fail. 2023 Sep;11(9):1181-1188. (PMID: 37589612) Adv Mater. 2023 Apr;35(16):e2207227. (PMID: 36314402) Circ Heart Fail. 2019 May;12(5):e005823. (PMID: 31104496) J Heart Lung Transplant. 2023 Apr;42(4):e1-e64. (PMID: 36805198) JACC Heart Fail. 2024 Mar;12(3):438-447. (PMID: 38276933) Med Care. 1997 Nov;35(11):1095-108. (PMID: 9366889) Circ Heart Fail. 2021 May;14(5):e007966. (PMID: 33951934) Circulation. 2013 Jun 18;127(24):2424-35. (PMID: 23697907) |
| Contributed Indexing: | Keywords: Markov model; cost-effectiveness; health economics; heart failure; heart transplantation; temporary mechanical circulatory support |
| Entry Date(s): | Date Created: 20260126 Date Completed: 20260701 Latest Revision: 20260701 |
| Update Code: | 20260701 |
| PubMed Central ID: | PMC12823849 |
| DOI: | 10.3389/fpubh.2025.1687327 |
| PMID: | 41584163 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!